NEW YORK, July 30, 2018 – Levi & Korsinsky announces a class action on behalf of all persons or entities who purchased or otherwise acquired securities of Rockwell Medical, Inc. (“Rockwell”) (NASDAQ: RMTI) between March 16, 2018 and June 26, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District court for the Eastern District of New York. To get more information about the RMTI lawsuit go to: http://www.zlk.com/pslra-d/rockwell-medical-inc or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
If you suffered a loss in Rockwell you have until September 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.